Partial EGFR inhibitors such as osimertinib promote the interaction of the E3 ubiquitin ligase MARCH8 with and polyubiquitination of PD-L1 for degradation by the proteasome pathway by inhibiting EGFR in EGFR-mutated non-small cell lung cancer[36]. Here, MARCHF8 is linked to non-small cell lung carcinoma.